In a patient with end‑stage renal disease and delirium, which antipsychotic medication should be given and which agents should be avoided?

Antipsychotic Selection in End-Stage Renal Disease with Delirium

In patients with end-stage renal disease and delirium, use haloperidol at reduced doses (0.25-0.5 mg PO/SC initially) or quetiapine (12.5-25 mg PO), while avoiding risperidone and amisulpride due to renal excretion concerns.

Preferred Agents

First-Line: Haloperidol

• Starting dose: 0.25-0.5 mg PO or SC (lower than standard 0.5-1 mg) 1
• PRN dosing: 0.25-0.5 mg q1h as needed
• Scheduled dosing: q8h-q12h if required
• Rationale: Haloperidol is hepatically metabolized, not dialyzable, and has the most evidence in medically ill patients 2, 3
• Monitoring: ECG for QTc prolongation, especially in ESRD patients 1

Alternative: Quetiapine

• Starting dose: 12.5-25 mg PO (reduced from standard 25 mg) 1
• Frequency: q12h if scheduled dosing needed
• Advantages: Less likely to cause extrapyramidal symptoms, hepatically metabolized 1
• Caution: More sedating; monitor for orthostatic hypotension (common in ESRD)

Second-Line: Olanzapine

• Starting dose: 2.5 mg PO/SC 1
• Advantages: Hepatic metabolism, dose reduction needed for hepatic but not specifically renal impairment 1
• Caution: Avoid combining with benzodiazepines due to risk of oversedation and respiratory depression 1

Agents to AVOID

Absolutely Avoid: Amisulpride

• Renally excreted and contraindicated in renal failure 4
• This is the only antipsychotic with explicit manufacturer warnings against use in renal failure

Use with Extreme Caution: Risperidone

• Requires dose reduction in severe renal impairment 1
• If used, start at 0.25 mg (half the usual 0.5 mg starting dose)
• Oral route only; active metabolites may accumulate 4

Avoid: Chlorpromazine

• Guidelines explicitly state "use with caution in patients with renal and hepatic impairment" 1
• High anticholinergic burden problematic in ESRD patients

Critical Dosing Principles for ESRD

General rule: Use no more than two-thirds of the maximum dose for patients with normal renal function 2

Key pharmacokinetic considerations:

• Most antipsychotics are fat-soluble and hepatically metabolized, making them relatively safe in ESRD 2
• Protein binding is impaired in ESRD, leading to higher free drug levels despite normal total levels 2
• Almost all antipsychotics are NOT dialyzable (exception: lithium, not relevant here) 4, 2

Practical Management Algorithm

1. Start with haloperidol 0.25-0.5 mg for acute agitation or perceptual disturbances
2. Use PRN dosing initially rather than scheduled dosing 1
3. Titrate gradually in 0.25-0.5 mg increments
4. Switch to quetiapine if extrapyramidal symptoms develop or if sedation is desired
5. Monitor closely: ECG, mental status, falls risk, paradoxical agitation
6. Discontinue as soon as possible - antipsychotics often continue unnecessarily after ICU discharge 5

Important Caveats

Do NOT use antipsychotics if:

• Patient has Parkinson's disease or dementia with Lewy bodies (high risk of severe extrapyramidal symptoms) 1

Recognize that:

• Antipsychotics themselves can worsen or cause delirium 1
• Evidence shows antipsychotics do NOT reduce delirium duration in critically ill patients 5, 6
• Use is justified only for distressing symptoms (hallucinations, severe agitation, risk to self/others) 1, 5

Benzodiazepines:

• Reserve for alcohol/benzodiazepine withdrawal delirium only 1
• Can worsen delirium in other contexts 1

The 2018 ESMO guidelines 1 provide the most comprehensive dosing table for delirium management, though they focus on cancer patients. The principles apply to ESRD patients with the critical modification of starting at lower doses due to altered protein binding 2. The 2018 Critical Care Medicine guidelines 5 specifically recommend AGAINST routine antipsychotic use for delirium treatment, supporting use only for distressing hyperactive symptoms.